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Abstract: The unique stereoelectronic properties of sp2-iminosugars enable their participation
in glycosylation reactions, thereby behaving as true carbohydrate chemical mimics. Among
sp2-iminosugar conjugates, the sp2-iminosugar glycolipids (sp2-IGLs) have shown a variety of
interesting pharmacological properties ranging from glycosidase inhibition to antiproliferative,
antiparasitic, and anti-inflammatory activities. Developing strategies compatible with molecular
diversity-oriented strategies for structure–activity relationship studies was therefore highly wanted.
Here we show that a reaction sequence consisting in stereoselective C-allylation followed by thiol-ene
“click” coupling provides a very convenient access to α-C-glycoside sp2-IGLs. Both the glycone
moiety and the aglycone tail can be modified by using sp2-iminosugar precursors with different
configurational profiles (d-gluco or d-galacto in this work) and varied thiols, as well as by oxidation of
the sulfide adducts (to the corresponding sulfones in this work). A series of derivatives was prepared
in this manner and their glycosidase inhibitory, antiproliferative and antileishmanial activities were
evaluated in different settings. The results confirm that the inhibition of glycosidases, particularly
α-glucosidase, and the antitumor/leishmanicidal activities are unrelated. The data are also consistent
with the two later activities arising from the ability of the sp2-IGLs to interfere in the immune system
response in a cell line and cell context dependent manner.
Keywords: sp2-Iminosugars; C-glycosides; glycolipids; glycomimetics; glycosidase inhibitors;
Leishmaniasis; cancer
1. Introduction
Since their conception in the mid-1990s, sp2-iminosugars have consolidated as a unique class
of glycomimetics in terms of chemical and structural versatility. Examples on record include
piperidine [1–4], pyrrolidine [5,6], pyrrolizidine [7,8], indolizidine [9–14], and nor-tropane cores [15–17]
with varied hydroxylation profiles. The presence of a pseudoamide-type nitrogen, with substantial
sp2-hybridized character, at the position of the ring oxygen in monosaccharides greatly facilitates
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the incorporation of substituents at the endocyclic heteroatom, providing a very convenient manner
to modulate their properties as regulators of carbohydrate processing enzymes. This strategy has
been exploited for the development of glycosidase activity enhancers as pharmacological chaperone
candidates against several lysosomal storage disorders [18–20], including Gaucher [21–26], Fabry [27,28],
GM1-gangliosidosis [29,30], Tay–Sachs [31], and α-mannosidosis [32] diseases. The pseudoamide
functional group additionally influences the stereoelectronic properties at the pseudoanomeric
region, which translates into an exacerbated anomeric effect that imparts a high chemical stability to
axially-oriented heteroatom substituents. Thus, sp2-iminosugars exist in reducing form (anomeric
OH) in aqueous solution and can engage in glycosylation reactions, thereby behaving as true
chemical sugar mimics wherein the pseudoamide function exerts strict control of the stereochemical
outcome to provide exclusively the α-anomer [33,34]. A variety of O-, S-, N-, and even C-glycoside
derivatives [35,36], including sp2-iminosugar disaccharide mimetics [37], multivalent systems [38–41],
glycopeptides (sp2-IGPs) [42], and glycolipids (sp2-IGLs) [43], have been prepared in this manner in
single diastereomeric form. For comparison, C-glycosides are the only representatives that are stable in
the case of classical iminosugars, but their stereoselective synthesis generally requires rather elaborated
reaction sequences [44–48].
The compatibility of the synthetic methodologies for the preparation of sp2-iminosugar
conjugates with structural diversity-oriented strategies has contributed decisively to expand
their range of biological activities. Notably, sp2-IGLs have shown to be potent antitumor,
antileishmanial, and anti-inflammatory agents [49,50] depending on the nature of the aglycone moiety.
For instance, the C-octyl pseudo-α-glycoside 5N,6O-oxomethylidenenojirimycin (ONJ) derivative
OC-ONJ (Figure 1) exhibited selective antimitotic, proapoptotic, and antimetastatic activities against
breast carcinoma in vitro (noninvasive MCF-7 and invasive MDA-MB-231 cell lines) and in vivo
(mice) [51,52]. Replacement of the pseudoanomeric carbon atom by sulfur (OS-ONJ; Figure 1)
additionally led to modest antiparasitic activity against intracellular amastigotes of Leishmania donovani
(EC50 = 73.3 µM) [53]. Increasing the length of the S-alkyl chain up to twelve carbon atoms (DS-ONJ)
and oxidation to the corresponding sulfone derivative (DSO2-ONJ) considerably improved the potency
as leishmanicidal (up to 5-fold) without reducing the antiproliferative efficiency against different
human tumor cell lines (GI50 < 20 µM). Although initially these behaviors were ascribed to the ability of
inhibiting α-glucosidase, further evidence suggested that this might not be the case, as illustrated by the
fact that the 5N,6O-oxomethylidenenojirimycin (OGJ) epimers (DS-OGJ and DSO2-OGJ, respectively,
displayed similar antiproliferative and antiparasitic trends (Figure 1). Here we report the synthesis
of new sp2-IGLs that combine the key structural features previously encountered responsible for the
mentioned biological activities, namely a C-glycosidic linkage and the presence of sulfide or sulfone
functionalities in the aglycone moiety by making use of the thiol-ene “click” reaction [54–59]. Precisely,
the ONJ (1–6) and OGJ (7–12) derivatives (Figure 2) have been prepared and evaluated in parallel for
their glycosidase inhibitory, antiproliferative and antileishmanial activities in an attempt to ascertain
whether or not the mechanisms at play are concurrent.
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Figure 1. Chemical structures and biological activities of featured sp2-IGLs.Molecules 2018, 23, x FOR PEER REVIEW  4 of 22 
 
 
Figure 2. Chemical structures of the pseudo-α-C-glycoside sp2-IGLs prepared in this work. 
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reactions [61] of 14 with octanethiol, dodecanethiol, and 2-[N-(tert-
butoxycarbonyl)amino]ethanethiol were conducted. The reaction conditions implied irradiation at 
365 nm in the presence of a catalytic amount of 2,2-dimethoxy-2-phenyl-acetophenone (DPAP) in dry 
DMF, leading to the expected anti-Markovnikov sulfide adducts 16, 17, and 18, respectively, in over 
90% yield. Conventional deacetylation reactions provided the fully unprotected α-C-glycoside 
derivatives 1, 2, and 3 (Scheme 1). Compounds 16–18 were further oxidized with m-
chloroperoxybenzoic acid (mCPBA) [53] to the corresponding sulfones 19–21, which after removal of 
the acetate groups gave the amphiphilic sp2-IGLs 4, 5, and 6 (Scheme 1). A parallel reaction sequence 
starting from the OGJ tetraacetate 22, let access the corresponding α-C-allyl glycoside (23, 24) and α-
C-glycoside sp2-IGL sulfide (25–27 and 7–9) and sulfone derivatives (28–30 and 10–12) with a 
substitution pattern of stereochemical complementarity to α-C-galactopyranosides (Scheme 2). 
Figure 2. Chemical structures of the pseudo-α-C-glycoside sp2-IGLs prepared in this work.
2. Results and Discussion
2.1. Synthesis
The C-allylation reaction of the ONJ tetraacetate 13 [33] by treatment with an excess of
allyltrimethylsilane [60] and boron trifluoride etherate (BF3·OEt2) at 80 ◦C proceeded with total
α-stereoselectivity to give the ivotal recursor 14 in high yield (Scheme 1). An aliquot of 14 was
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deacetylated to afford the unprotected C-allyl ONJ 15, used as control in subsequent pharmacological
tests. The corresponding NMR data were in full agreement with the proposed structure. Particularly,
the vicinal coupling constant value between the anomeric H-1 proton and H-2 (6.0 and 6.6 Hz for 14
and 15, respectively) support their gauche relative disposition characteristic of α-gluco arrangements
in the 4C1 chair conformation. In order to access the target sp2-IGLs, photoinduced thiol-ene coupling
reactions [61] of 14 with octanethiol, dodecanethiol, and 2-[N-(tert-butoxycarbonyl)amino]ethanethiol
were conducted. The reaction conditions implied irradiation at 365 nm in the presence of a catalytic
amount of 2,2-dimethoxy-2-phenyl-acetophenone (DPAP) in dry DMF, leading to the expected
anti-Markovnikov sulfide adducts 16, 17, and 18, respectively, in over 90% yield. Conventional
deacetylation reactions provided the fully unprotected α-C-glycoside derivatives 1, 2, and 3 (Scheme 1).
Compounds 16–18 were further oxidized with m-chloroperoxybenzoic acid (mCPBA) [53] to the
corresponding sulfones 19–21, which after removal of the acetate groups gave the amphiphilic sp2-IGLs
4, 5, and 6 (Scheme 1). A parallel reaction sequence starting from the OGJ tetraacetate 22, let access
the corresponding α-C-allyl glycoside (23, 24) and α-C-glycoside sp2-IGL sulfide (25–27 and 7–9) and
sulfone derivatives (28–30 and 10–12) with a substitution pattern of stereochemical complementarity
to α-C-galactopyranosides (Scheme 2).Molecules 2018, 23, x FOR PEER REVIEW  5 of 22 
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2.2. Inhibitory Properties against Commercial Enzymes
The inhibitory properties of the new sp2-IGLs 1–12 and the α-C-allyl ONJ and OGJ glycosides 15,
and 24 were examined against a panel of commercial glycosidases that included the α-glucosidases
maltase (Saccharomyces cerevisiae) and amyloglucosidase (Aspergillus niger), the β-glucosidases from
almonds and bovine liver, α-galactosidase from green coffee beans, β-galactosidase from Escherichia
coli, α-mannosidase from Jack beans, and β-mannosidase from Helix pomatia. The corresponding
inhibition constant (Ki) values are collected in Table 1.
Table 1. Glycosidase inhibitory activities (Ki, µM) of the new ONJ (1–6, 15) and OGJ (7–12, 24)
C-glycoside derivatives. Values represent the mean± SD (three independent determinations). Inhibition
was competitive in all cases.
Compound a α-Glcase (Yeast Maltase) β-Glcase (Bovine Liver)
15 79 ± 8 n.i.
1 0.34 ± 0.02 400 ± 20
2 0.74 ± 0.03 54 ± 5
3 0.28 ± 0.02 151 ± 10
4 2.6 ± 0.3 172 ± 14
5 2.5 ± 0.2 85 ± 18
6 0.75 ± 0.02 342 ± 20
7 n.i. n.i.
8 n.i. 53 ± 12
9 n.i. n.i.
10 n.i. 422 ± 22
11 n.i. 134 ± 10
12 n.i. 770 ± 45
24 n.i. n.i.
a No inhibition was observed for any compound at 1 mM concentration on Aspergillus niger amyloglucosidase,
almond β-glucosidase, green coffee bean α-galactosidase, E. coli β-galactosidase, Jack bean α-mannosidase, and Helix
pomatia β-mannosidase.
None of ONJ sp2-IGLs 1–6 showed inhibition towardsα- orβ-mannosidase orα- orβ-galactosidase,
in agreement with their d-gluco configurational pattern. They behaved instead as low-micromolar
to nanomolar inhibitors of yeast maltase (Ki 2.6–0.28 µM). The presence of the lipidic aglycone was
determinant for the inhibitory potency, since the parent α-C-allyl derivative 15 was a 30- to 100-fold
weaker inhibitor of this enzyme (Ki 79 µM). The sulfone derivatives 4–6 behaved as less potent maltase
inhibitors than the corresponding sulfides 1–3, probably because of their moderated lipophilicity.
Compounds 1–6 were much weaker inhibitors of β-glucosidase (bovine liver), with Ki values in the
54 to 400 µM range, meaning α:β anomeric selectivity ratios about 100:1. Neither epimeric OGJ
sp2-IGLs 7–12 nor α-allyl OGJ glycoside 24 behaved as inhibitors of the α-galactosidase used in this
assay, in spite of the configurational complementarity with the natural substrates. This is consistent
with previous reports on the inhibitory properties of galacto-configured sp2-iminosugars showing
that α-galactosidase inhibition is totally cancelled after engaging the primary hydroxyl in closing
de five-membered ring [62]. As expected, the OGJ α-C-glycosides did not inhibit α-glucosidase,
β-galactosidase or α- or β-mannosidase, although some representatives exhibited modest inhibition
of the mammalian β-glucosidase (Ki 53 to 422 µM), an enzyme known to accept both β-d-gluco and
β-d-galacto substrates [63].
2.3. Antiproliferative Activity
The antiproliferative activity of all the sp2-iminosugar C-glycosides (1–12) was evaluated against
a panel of six representative human solid tumor cell lines including lung (A549 and SW1573),
breast (HBL-100, T-47D), cervix (HeLa), and colon (WiDr). The results, expressed as the concentration
to achieve 50% growth inhibition (GI50), are shown in Figure 3; only GI50 values below 100 µM are
considered significant.
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The new α-C-glycoside sp2-IGLs included in this study were found not to affect the viability and
mortality of the breast normal cell line (MCF-10A) at concentrations up to 100 µM. The ensemble of
data revealed a strong dependence of the antiproliferative activity against tumor cells on the nature
of the aglycone substituent. Comparatively, the effect of the configurational hydroxylation profile
of the glycone moiety (d-gluco for the ONJ derivatives 1–6; d-galacto for the OGJ derivatives 7–12) is
much less marked. The carbamate-containing sp2-IGLs 3, 6, 9, and 12 did not show any significant
antiproliferative activity in this assay. Conversely, the octyl (1,7) and dodecyl sulfides (2,8) were active
against all the assayed tumor cell lines, with GI50 values ranging from 14 to 54 µM for the first pair
and from 9.6 to 19 µM for the second pair, highlighting an increase in the antiproliferative activity
with lipophilicity. This trend becomes much more pronounced in the sulfone series: whereas the
octylsufonyl sp2-IGLs 4 and 10 did not achieve 50% tumor cell growth inhibition below the 100 µM
concentration threshold, dodecylsulfonyl homologs 5 and 11 exhibited GI50 values in the range of 26
to 82 µM.
Inhibition of theα-glycosidases involved inN-glycoprotein biosynthesis, includingα-glucosidases,
has been invoked to explain the antitumor effects of some classical iminosugar glycomimetics [64,65].
Although the α-glucosidase inhibitory potency and antiproliferative activities of the ONJ derivatives
both increased with aglycone lipophilicity, at least for the sulfide and sulfone representatives,
close inspection of the data discards any direct relationship between them in the case of the sp2-IGLs.
For instance, compounds 2 and 8 have very similar broad range antiproliferative profiles (Figure 3),
but whereas 2 is a nanomolar competitive inhibitor of maltase, 8 did not inhibit this enzyme (Table 1).
Even more revealing, compound 3, the most potent α-glucosidase inhibitor of the library (Ki 0.28 µM),
was out of range in the antiproliferative assay. These evidences strongly suggest that the mechanism
responsible for the antiproliferative outcome of sp2-IGLs in cancer cell lines is glycosidase-independent.Molecules 2018, 23, x FOR PEER REVIEW  7 of 22 
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2.4. Antileishmanial Activity and Cellular Toxicity
The leishmanicidal activity of a l th synthesized sp2-iminosugarC-glycosides (1–12) was evaluat d
ag inst intracellular amastigotes of Leishmania donovani MHOM/ET/67/HU3 line with luciferase gene
integrated into the parasit geno e [66]. To this end, the conc ntration of c mpound required to inhibit
the growth of parasites by 50% (50% effectiv concentration; EC50) was det rmine , with a threshold
established at 20 µM (Table 2). A str g i fluence of the nature of the lipid chain α-linked to the
pseudoanomeric position of the bicyclic core in the sp2-IGLs was inferred from the corresponding data.
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Thus, the 3-thiadodecyl (1 and 7) or the 3-thia-6-[N-(tert-butoxycarbonyl)amino]hexyl α-C-glycosides
(3 and 9) promoted potent inhibition of the parasite growth, with EC50 values in the low micromolar
range (7–15 µM), regardless of the configurational pattern of the sp2-iminosugar aglycone moiety
(ONJ for 1 and 3; DGJ for 7 and 9). The longer-chain sp2-IGLs 2 and 8 were over the 20 µM
concentration threshold in this assay. In the sulfone series, the results evidenced some disparity
between the ONJ and OGJ epimers. Thus, the octylsulfonyl and dodecylsulfonyl segment-bearing
derivatives 5 (EC50 11.44 ± 5.08 µM) and 10 (EC50 13.81 ± 1.72 µM) were the only representatives
with EC50 values below the 20 µM threshold in the first and second case, respectively. Although the
antileishmanial activity is modest as compared to the reference drug amphotericin B (AmB, Table 2),
all sp2-IGLs exhibited lower toxicities in the monocytic leukemia (THP-1) cell line, broadly used as
a model for human monocytes to assess potential toxic side-effects of antileishmanial drug candidates,
and in human lung fibroblast MRC-5 cells (Table 2).
Table 2. Drug susceptibility profile of the C-glycosides sp2-IGLs 1–12 for intracellular amastigotes
of L. donovani (EC50 values, µM) and cellular toxicity (MTT assay) in THP-1 and MRC-5 cells
(EC50 values, µM). Data for the reference drug AmB are also shown a.
Compound Intracellular Amastigotes THP-1 (SI) MRC-5 (SI)
1 7.68 ± 0.29 130.96 ± 4.29 (17.06) 32.20 ± 1.03 (4.19)
2 >20 72.24 ± 4.18 (<3.61) 19.92 ± 2.76 (<1)
3 14.96 ± 1.28 >200 133.89 ± 6.02 (8.95)
4 >20 >200 188.98 ± 15.59 (<9.45)
5 11.44 ± 5.08 100.43 ± 10.87 (8.78) 71.49 ± 3.75 (6.25)
6 >20 >200 155.18 ± 3.10 (<7.76)
7 10.58 ± 1.51 127.55 ± 5.71 (12.06) 60.44 ± 2.80 (5.72)
8 >20 68.30 ± 3.04 (<3.42) 32.08 ± 1.94 (<1.60)
9 13.39 ± 1.13 >200 139.92 ± 17.31 (10.44)
10 13.81 ± 1.72 >200 184.97 ± 21.25 (13.40)
11 >20 >200 161.89 ± 20.18 (<8.10)
12 >20 >200 181.51 ± 14.93 (<9.08)
AmB 0.15 ± 0.01 20.07 ± 4.43 (133.80) 16.93 ± 2.44 (112.87)
a Parasites were grown as described in the Experimental section for 72 h at 37 ◦C in the presence of increasing
concentrations of compounds. THP-1 and MRC-5 cells were grown as described in the Experimental section for
72 h at 37 ◦C, in the presence of increasing concentrations of compounds. Cell viability was determined using the
luciferase assay (intracellular amastigotes). AmB was used as the reference antileishmanial agent. Data are means
of EC50 ± SD from three independent experiments. SI: Selectivity Index (EC50 THP-1 or MRC-5/EC50 parasite).
While it is apparent that the antiparasitic activity data in Table 2 do not correlate with the
α-glucosidase inhibitory activity data in Table 1, it is less obvious to discern from the ensemble of
results whether or not the antiproliferative and antileishmanial activities of the sp2-IGLs share common
molecular mechanisms. The fact that both cancer and parasite infection lead to subversion of the
innate immune system suggests that the compounds act as immunoregulators, as reported for other
drugs displaying anticancer and antileishmanial behaviors, e.g., the alkyl lipid ethers miltefosine
and perifosine [67]. Indeed, the sp2-IGL representative DSO2-ONJ (Figure 1), which also displayed
antiproliferative and antileishmanial activities [43,53], was found to behave as a toll-like receptor-4
(TLR4) antagonist in LPS-induced inflammation models in microglia and dendritic cells, as well as
in a mouse model of acute inflammation, displaying potent anti-inflammatory activity [49]. Biochemical
and computational data pointed at the p38 mitogen activated protein kinase (MAPK), a master regulator
of the immune response, as the putative target. Considering that p38 is also involved in cancer and
parasite infection, it seems likely that sp2-IGL binding to p38 is responsible for the ensemble of the
observed pharmacological properties. Notwithstanding, a comparative analysis of the results collected
in Figure 3 and Table 2 reveals significant differences in the antiproliferative and antileishmanial activity
trends of the new sp2-IGL 1–12 as a function of their structure. In both cases, the efficacy depends
essentially of the aglycone nature, whereas the configuration of the glycone configuration—ONJ or
OGJ—is much less influential. Yet, whereas the antitumor potency follows the tendency dictated by
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aglycone lipophilicity, the antiparasitic efficiency is less predictable and more sensitive to the aglycone
structure. For instance, the derivatives combining a sulfide and a carbamate group in the lipid chain
(3 and 9), which did not display significant antiproliferative activity against any of the solid tumor
cells assayed (see previous section), are low micromolar antileishmanial agents (EC50 14.96 ± 1.28 and
13.39 ± 1.13 µM, respectively). In contrast, the oxidized sulfone counterparts 6 and 12 were over the
20 µM threshold in the antileishmanial assayed. It should be considered that other factors, such as
membrane-crossing or membrane-insertion capabilities, can strongly influence the biological activities
of glycolipids in a cell line and cell-context dependent manner and can be also at the origin of the
differences observed between both assays.
In summary, the results here presented demonstrate the suitability of the C-allylation of
sp2-iminosugars in combination with the thiol-ene click reaction to access α-C-glycoside sp2-IGLs in
high yield and with total stereocontrol, providing a versatile strategy to assess their pharmacological
properties. The glycosidase inhibitory, antiproliferative and antileishmanial activities can be then
optimized either individually or concertedly. The biological data support that the capabilities to
inhibit glycosidases and the abilities to act as immunoregulators in the context of cancer or parasite
infection are independent, opening the possibility of purposely designing multitarget compounds.
It is conceivable, for instance, that sp2-IGLs behaving concomitantly as immunostimulants and
inhibitors of a glycosidase involved in cancer or parasite cell metabolism will lead to more efficient
therapeutics. Work in this direction is currently sought in our laboratories.
3. Materials and Methods
3.1. General Methods
Reagents and solvents were purchased from commercial sources and used without further
purification. Optical rotations were measured with a JASCO P-2000 polarimeter, using a sodium lamp
(λ = 589 nm) at 22 ◦C in 1 cm or 1 dm tubes. NMR experiments were performed at 300 (75.5), 400
(100.6) and 500 (125.7) MHz. 1-D TOCSY, as well as 2-D COSY and HMQC, experiments were carried
out to assist signal assignment. For ESI mass spectra, 0.1 pm sample concentrations were used, the
mobile phase consisting of 50% aq MeCN at 0.1 mL/min. Thin-layer chromatography was performed
on precoated TLC plates, silica gel 30F-245, with visualization by UV light and also with 10% H2SO4 or
0.2% w/v cerium (IV) sulfate–5% ammonium molybdate in 2 m H2SO4, or 0.1% ninhydrin in EtOH.
Column chromatography was performed on Chromagel (silice 60 AC.C 70–200 µM). Deacetylation
reactions were carried out by using Zemplén procedure, e.i., addition of NaOMe (0.1 equiv. per
mol of acetate) in MeOH at room temperature and neutralization with solid CO2, evaporation of
the solvent and purification by column chromatography. All compounds were purified to ≥95%
purity as determined by elemental microanalysis results obtained on a CHNS-TruSpect® Micro
elemental analyzer (Instituto de Investigaciones Químicas de Sevilla, Spain) from vacuum-dried
samples. The analytical results for C, H, N and S were within ± 0.4 of the theoretical values.
(1R)-1,2,3,4-Tetra-O-acetyl-5N,6O-oxomethylidenegluco(galacto)nojirimycin (13 and 22, respectively)
were prepared according reported procedures [33,68].
Inhibition constant (Ki) values were determined by spectrophotometrically measuring the residual
hydrolytic activities of the glycosidases against the respective o- (for β-galactosidase from E. coli) or
p-nitrophenyl α- or β-d-glycopyranoside (for other glycosidases) in the presence of the iminosugars.
Each assay was performed in phosphate buffer or phosphate-citrate buffer (for α- or β-mannosidase
and amyloglucosidase) at the optimal pH for the enzymes. The reactions were initiated by addition of
the enzyme to a solution of the substrate in the absence or presence of various inhibitor concentrations.
The mixture was incubated for 10–30 min at 37 ◦C or 55 ◦C (for amyloglucosidase) and the reaction
was quenched by addition of 1 m Na2CO3. Reaction times were appropriate to obtain 10–20%
conversion of the substrate in order to achieve linear rates. The absorbance of the resulting mixture was
determined at 405 nm. Approximate value of Ki was determined from the slope of Dixon plots using
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a fixed concentration of substrate (around the Km value for the different glycosidases) and various
concentrations of inhibitor. Full Ki determinations and enzyme inhibition mode were determined from
the slope of Lineweaver–Burk plots and double reciprocal analysis. Representative examples of Dixon
and Lineweaver–Burk plots are shown in the Supplementary materials.
3.2. Statistical Analysis
All results are expressed as mean ± SD of three independent experiments, each conducted in
triplicate. The measurements were statistically analyzed using the Student’s t-test for comparing
2 groups. The level of significance was set at p < 0.05.
3.3. General Procedure for the Synthesis of the Allylated ONJ and OGJ Precursors 14 and 23
To a solution of 13/22 (2.20 mmol) in anhydrous CH3CN (36 mL) under Ar atmosphere,
allyltrimethylsilane (3.5 mL, 22 mmol) and BF3.Et2O (2.8 mL) were added at rt and the mixture
was then heated at 80 ◦C for 20 min. The reaction mixture was diluted with EtOAc (50 mL) and
quenched with saturated aqueous NaHCO3 (2 × 30 mL). The organic phase was separated and the
aqueous phase extracted with EtOAc (3 × 25 mL). The combined organic layer was washed with water
(25 mL) and brine (25 mL), dried (MgSO4) and concentrated under reduced pressure. The resulting
residue was purified by column chromatography using the solvent indicated in each case to give the
corresponding C-allylated pseudo-α-glycosides.
(1R)-2,3,4-Tri-O-acetyl-1-allyl-5N,6O-oxomethylidene-1-deoxynojirimycin (14). Purification by column
chromatography (1:1 EtOAc-cyclohexane) afforded 14. Yield: 712 mg (91%); Rf = 0.60
(2:1 EtOAc-cyclohexane). [α]D + 34.0 (c 1.0 in DCM); 1H NMR (500 MHz, CDCl3) δ 5.72 (dddd,
1 H, Jc,d = 17.0 Hz, Jc,e = 10.0 Hz, Jc,b = 8.0 Hz, Jc,a = 5.5 Hz, CH(c)=CH2), 5.34 (t, 1 H, J2,3 = J3,4 = 10.0 Hz,
H-3), 5.14 (d, 1 H, CH=CH2(d)), 5.11 (d, 1 H, CH=CH2(e)), 5.06 (dd, 1 H, J1,2 = 6.0 Hz, H-2), 4.93 (t, 1 H,
J4,5 = 10.0 Hz, H-4), 4.41–4.33 (m, 2 H, H-1, H-6a), 4.22 (dd, 1 H, J6a,6b = 9.5 Hz, J5,6b = 5.0 Hz, H-6b),
3.81 (ddd, 1 H, J5,6a = 8.5 Hz, H-5), 2.52 (dt, 1 H, Ja,b = 15.0 Hz, Ja,1 = 5.0 Hz, CH2(a)CH=CH2),
2.34 (ddd, 1 H, Jb,1 = 11.5 Hz, CH2(b)CH=CH2), 2.05–2.02 (3 s, 9 H, MeCO); 13C NMR (125.7 MHz,
CDCl3) δ 170.0-169.2 (CO ester), 156.2 (CO carbamate), 132.8 (CH=CH2), 118.5 (CH=CH2), 72.5 (C-4),
69.9–69.5 (C-2, C-3), 65.7 (C-6), 52.1 (C-5), 50.0 (C-1), 30.7 (CH2CH=CH2), 20.6 (MeCO); ESIMS: m/z
378.28 [M + Na]+; Anal. Calcd for C16H21NO8: C 54.08, h 5.96, N 3.94; found: C 54.22, h 6.08, N 3.71.
(1R)-2,3,4-Tri-O-acetyl-1-allyl-5N,6O-oxomethylidene-1-deoxygalactonojirimycin (23). Purification by
column chromatography (1:2→ 2:1 EtOAc-cyclohexane) afforded 23. Yield: 344 mg (95%); Rf = 0.63
(2:1 EtOAc-cyclohexane); [α]D + 64.7 (c 1.0 in DCM); 1H NMR (300 MHz, CDCl3) δ 5.71 (dddd, 1 H,
Jc,d = 17.1 Hz, Jc,e = 10.2 Hz, Jc,b = 8.1 Hz, Jc,a = 5.4 Hz, CH(c)=CH2), 5.38 (t, 1 H, J3,4 = J4,5 = 2.1 Hz,
H-4), 5.30 (dd, 1 H, J2,3 = 10.8 Hz, J1,2 = 6.6 Hz, H-2), 5.12 (m, 3 H, H-3, CH=CH2), 4.49 (ddd, 1 H,
J1,b = 11.1 Hz, J1,a = 4.5 Hz, H-1), 4.31 (t, 1 H, J6a,6b = J5,6a = 8.5 Hz, H-6a), 4.02 (m, 2 H, H-5, H-6b),
2.48 (m, 1 H, CH2(a)CH=CH2), 2.27 (ddd, 1 H, Ja,b = 15.0 Hz, Jb,H1 = 11.5 Hz, CH2(b)CH=CH2),
2.15–1.98 (3 s, 9 H, MeCO); 13C NMR (75.5 MHz, CDCl3) δ 170.5-169.3 (CO ester), 156.6 (CO carbamate),
133.2 (CH=CH2), 118.3 (CH=CH2), 68.9 (C-4), 68.5 (C-3), 66.5 (C-2), 62.6 (C-6), 51.1 (C-5), 50.3 (C-1),
30.4 (CH2CH=CH2), 20.7-20.6 (MeCO); ESIMS: m/z 378.26 [M + Na]+; Anal. Calcd for C16H21NO8: C
54.08, h 5.96, N 3.94. Found: C 54.11, h 6.03, N 3.90.
(1R)-1-Allyl-5N,6O-oxomethylidene-1-deoxynojirimycin (15). Compound 15 was obtained by
conventional O-deacetylation of 14 (51 mg, 0.14 mmol), as described in general methods, followed
by purification by column chromatography (25:1 EtOAc-MeOH). Yield: 33 mg (quant); Rf = 0.26
(25:1 EtOAc-MeOH); [α]D + 22.0 (c 1.1 in MeOH); 1H NMR (300 MHz, CD3OD) δ 5.76 (dddd, 1 H,
Jc,d = 17.1 Hz, Jc,e = 10.2 Hz, Jc,a = 8.1 Hz, Jc,b = 5.7 Hz, CH(c)=CH2), 5.14 (dd, 1 H, Jd,b = 1.2 Hz,
CH=CH2(d)), 5.05 (d, 1 H, CH=CH2(e)), 4.43 (t, 1 H, J6a,6b = J5,6a = 8.5 Hz, H-6a), 4.27 (dd, 1 H,
J5,6b = 4.2 Hz, H-6b), 4.00 (ddd, 1 H, J1,a = 12.3 Hz, J1,2 = 5.4 Hz, J1,b = 3.6 Hz, H-1), 3.65 (ddd, 1 H,
J4,5 = 9.5 Hz, H-5), 3.57–3.43 (m, 2 H, H-2, H-3), 3.24 (t, 1 H, J3,4 = 9.0 Hz, H-4), 2.66 (dddd, 1 H,
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Ja,b = 15.0 Hz, CH2(b)CH=CH2), 2.21 (ddd, 1 H, CH2(a)CH=CH2); 13C NMR (75.5 MHz, CD3OD) δ 159.5
(CO), 136.0 (CH=CH2), 117.7 (CH=CH2), 75.5 (C-4), 74.7–72.0 (C-2, C-3), 67.5 (C-6), 55.2–55.0 (C-1, C-5),
30.5 (CH2CH=CH2); ESIMS: m/z 252.2 [M + Na]+; Anal. Calcd for C10H15NO5: C 52.40, h 6.60, N 6.11.
Found: C 52.28, h 6.73, N 5.87.
(1R)-1-Allyl-5N,6O-oxomethylidene-1-deoxygalactonojirimycin (24). Compound 24 was obtained
by conventional O-deacetylation of 23 (33 mg, 0.09 mmol) followed by purification by column
chromatography (30:1 EtOAc-MeOH). Yield: 21 mg (quant); Rf = 0.22 (30:1 EtOAc-MeOH); [α]D − 3.0
(c 1.0 in MeOH); 1H NMR (300 MHz, CDCl3) δ 5.78 (dddd, 1 H, Jc,d = 18.3 Hz, Jc,e = 10.2 Hz, Jc,b = 8.3 Hz,
Jc,a = 5.6 Hz, CH(c)=CH2), 5.15 (m, 1 H, CH=CH2(d)), 5.06 (m, 1 H, CH=CH2(e)), 4.41 (dd, 1 H,
J6a,6b = 8.6 Hz, J5,6a = 4.6 Hz, H-6a), 4.34 (t, 1 H, J5,6b = 8.6 Hz, H-6b), 4.08 (m, 1 H, H-1), 4.02 (ddd, 1 H,
J4,5 = 2.3 Hz, H-5), 3.96 (dd, 1 H, J2,3 = 9.9 Hz, J1,2 = 6.4 Hz, H-2), 3.82 (t, 1 H, J3,4 = 2.3 Hz, H-4),
3.65 (dd, 1 H, H-3), 2.65 (m, 1 H, CH2(b)CH=CH2), 2.24 (ddd, 1 H, Ja,b = 14.6 Hz, Jb,H1 = 12.0 Hz,
CH2(a)CH=CH2); 13C NMR (75.5 MHz, CDCl3) δ 160.3 (CO), 136.4 (CH=CH2), 117.6 (CH=CH2),
71.5 (C-3), 71.1 (C-4), 68.1 (C-2), 64.8 (C-6), 54.9 (C-5), 54.5 (C-1), 30.1 (CH2CH=CH2); ESIMS: m/z 252.20
[M + Na]+; Anal. Calcd for C10H15NO5: C 52.40, h 6.60, N 6.11. Found: C 52.09, h 6.38, N 5.85.
3.4. General Procedure for the Synthesis of ONJ (1–3) and OGJ Derivatives (7–9) by Photoinduced
Thiol-Ene Reaction
To a stirred solution of the corresponding pseudo-α-C-allyl glycosides 14/23 (142 mg, 0.40 mmol)
and 2,2-dimethoxy-2-phenyl-acetophenone (DPAP) (31 mg, 0.12 mmol) in anhydrous DMF (2.5 mL),
the corresponding thiol (1.20 mmol) was added. The mixture was deoxygenated for 30 min and then
irradiated at rt under UVA lamp (λ 365 nm) for 1 h. The solvent was removed and the residue was
purified by column chromatography using (1:5→ 1:3→1:1 EtOAc:cyclohexane) as eluent.
(1R)-2,3,4-Tri-O-acetyl-1-[3-(octylthio)propyl]-5N,6O-oxomethylidene-1-deoxynojirimycin (16). Yield:
70 mg (99%); Rf = 0.74 (2:1 EtOAc-cyclohexane); [α]D + 42.2 (c 1.0 in DCM); 1H NMR (300 MHz, CDCl3)
δ 5.31 (t, 1 H, J2,3 = J3,4 = 10.0 Hz, H-3), 5.01 (dd, 1 H, J1,2 = 6.3 Hz, H-2), 4.94 (t, 1 H, J4,5 = 10.0 Hz, H-4),
4.38 (dd, 1 H, J6a,6b = 9.0 Hz, J5,6a = 8.1 Hz, H-6a), 4.31–4.20 (m, 1 H, H-1), 4.25 (dd, 1 H, J5,6b = 4.5 Hz,
H-6b), 3.85 (1 H, ddd, H-5), 2.66–2.43 (m, 4 H, CH2SCH2), 2.00–1.96 (3 s, 9 H, MeCO), 1.90–1.20 (m, 16
H, CH2), 0.87 (t, 3 H, 3JH,H = 7.0 Hz, CH3); 13C NMR (75.5 MHz, CDCl3) δ 169.9–169.2 (CO ester), 156.3
(CO carbamate), 72.3 (C-4), 69.8 (C-3), 69.6 (C-2), 65.6 (C-6), 52.1 (C-5), 50.7 (C-1), 32.2–22.6 (CH2), 20.6
(MeCO), 14.1 (CH3); ESIMS: m/z 524.39 [M + Na]+; Anal. Calcd for C24H39NO8S: C 57.46, h 7.84, N
2.79, S, 6.39. Found: C 57.61, h 8.00, N 2.48, S, 6.13.
(1R)-2,3,4-Tri-O-acetyl-1-[3-(dodecylthio)propyl]-5N,6O-oxomethylidene-1-deoxynojirimycin (17).
Yield: 118 mg (96%); Rf = 0.58 (1:1 EtOAc-cyclohexane). [α]D + 37.5 (c 1.1 in DCM); 1H NMR
(300 MHz, CDCl3) δ 5.30 (t, 1 H, J2,3 = J3,4 = 9.6 Hz, H-3), 5.00 (dd, 1 H, J1,2 = 6.3 Hz, H-2), 4.94 (t, 1 H,
J4,5 = 9.6 Hz, H-4), 4.37 (dd, 1 H, J6a,6b = 9.0 Hz, J5,6a = 8.1 Hz, H-6a), 4.30–4.20 (m, 1 H, H-1),
4.23 (dd, 1 H, J5,6b = 4.5 Hz, H-6b), 3.84 (1 H, ddd, H-5), 2.65–2.42 (m, 4 H, CH2SCH2), 2.05–2.01 (3 s, 9 H,
MeCO), 1.90–1.20 (m, 24 H, CH2), 0.86 (t, 3 H, 3JH,H = 7.0 Hz, CH3); 13C NMR (75.5 MHz, CDCl3) δ
169.9–169.2 (CO ester), 156.3 (CO carbamate), 72.3 (C-4), 69.8 (C-3), 69.5 (C-2), 65.6 (C-6), 52.1 (C-5),
50.7 (C-1), 32.2–22.7 (CH2), 20.6–20.5 (MeCO), 14.1 (CH3); ESIMS: m/z 580.43 [M + Na]+; Anal. Calcd
for C28H47NO8S: C 60.30, h 8.49, N 2.51, S 5.75. Found: C 60.54, h 8.63, N 2.36, S 5.49.
(1R)-2,3,4-Tri-O-acetyl-1-[3-(N-tert-butoxycarbonylaminoethylthio)propyl]-5N,6O-
oxomethylidene-1-deoxynojirimycin (18). Yield: 218 mg (94%); Rf = 0.39 (1:1 EtOAc-cyclohexane);
[α]D + 36.5 (c 1.1 in DCM); 1H NMR (300 MHz, CDCl3) δ 5.30 (t, 1 H, J2,3 = J3,4 = 9.6 Hz, H-3),
5.00 (dd, 1 H, J1,2 = 6.0 Hz, H-2), 4.95 (t, 1 H, J4,5 = 9.6 Hz, H-4), 4.40 (dd, 1 H, J6a,6b = 9.3 Hz,
J5,6a = 8.1 Hz, H-6a), 4.30–4.20 (m, 2 H, H-1, H-6b), 3.84 (ddd, 1 H, J5,6b = 4.2 Hz, H-5), 3.28 (q, 2 H,
J = 6.5 Hz, CH2NHBoc), 2.70–2.46 (m, 4 H, CH2SCH2), 2.06–2.01 (3 s, 9 H, MeCO), 1.90–1.57 (m, 4 H,
CH2), 1.43 (s, 9 H, CMe3); 13C NMR (75.5 MHz, CDCl3) δ 169.9–169.2 (CO ester), 156.3, 155.8 (CO
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carbamate), 79.4 (CMe3), 72.3 (C-4), 69.8 (C-3), 69.6 (C-2), 65.6 (C-6), 52.0 (C-5), 50.5 (C-1), 39.8
(CH2NHBoc), 32.1, 30.9 (CH2), 28.4 (CMe3), 25.3, 24.0 (CH2), 20.7–20.6 (MeCO); ESIMS: m/z 555.28
[M + Na]+; Anal. Calcd for C23H36N2O10S: C 51.87, h 6.81, N 5.26, S 6.02. Found: C 51.71, h 6.99,
N 4.97, S 5.78.
(1R)-2,3,4-Tri-O-acetyl-1-[3-(octylthio)propyl]-5N,6O-oxomethylidene-1-deoxygalactonojirimycin (25).
Yield: 188 mg (94%); Rf = 0.59 (1:1 EtOAc-cyclohexane); [α]D + 77.7 (c 1.0 in DCM); 1H NMR (300 MHz,
CDCl3) δ 5.37 (t, 1 H, J3,4 = J4,5 = 2.7 Hz, H-4), 5.25 (dd, 1 H, J2,3 = 10.9 Hz, J1,2 = 6.3 Hz, H-2), 5.10 (dd, 1 H,
H-3), 4.34 (m, 1 H, H-1), 4.33 (t, 1 H, J6a,6b = J5,6a = 9.0 Hz, H-6a), 4.10 (m, 1 H, H-5), 4.01 (dd, 1 H,
J5,6b = 3.5 Hz, H-6b), 2.52 (m, 4 H, CH2SCH2), 2.14–1.95 (3 s, 9 H, MeCO), 1.83–1.47 (m, 6 H, CH2),
1.32 (m, 10 H, CH2), 0.84 (t, 3 H, 3JH,H = 7.0 Hz, CH3); 13C NMR (75.5 MHz, CDCl3) δ 170.4–169.4 (CO
ester), 156.8 (CO carbamate), 69.0 (C-4), 68.4 (C-3), 66.5 (C-2), 62.3 (C-6), 51.0 (C-5), 50.8 (C-1), 32.1–22.6
(CH2), 20.7–20.5 (MeCO), 14.1 (CH3); ESIMS: m/z 524.33 [M + Na]+; Anal. Calcd for C24H39NO8S: C
57.46, h 7.84, N 2.79. S, 6.39. Found: C 57.57, h 8.03, N 2.56, S 6.04.
(1R)-2,3,4-Tri-O-acetyl-1-[3-(dodecylthio)propyl]-5N,6O-oxomethylidene-1- deoxygalactonojirimycin
(26). Yield: 205 mg (92%); Rf = 0.69 (1:1 EtOAc-cyclohexane); [α]D + 63.8 (c 1.0 in DCM); 1H NMR
(300 MHz, CDCl3) δ 5.34 (t, 1 H, J3,4 = J4,5 = 2.7 Hz, H-4), 5.23 (dd, 1 H, J2,3 = 10.9 Hz, J1,2 = 6.4 Hz,
H-2), 5.07 (dd, 1 H, H-3), 4.30 (m, 1 H, H-1), 4.29 (t, 1 H, J6a,6b = J5,6a = 8.9 Hz, H-6a), 4.04 (m, 1 H, H-5),
3.97 (dd, 1 H, J5,6b = 3.5 Hz, H-6b), 2.49 (m, 4 H, CH2S), 2.11–1.93 (3 s, 9 H, MeCO), 1.85–1.45 (m, 6 H,
CH2), 1.25 (m, 18 H, CH2), 0.81 (t, 3 H, 3JH,H = 7.0 Hz, CH3); 13C NMR (75.5 MHz, CDCl3) δ 170.5–169.4
(CO ester), 156.8 (CO carbamate), 69.0 (C-4), 68.4 (C-3), 66.5 (C-2), 62.8 (C-6), 51.1 (C-5), 50.9 (C-1),
32.2–22.7 (CH2), 20.7–20.5 (MeCO), 14.1 (CH3); ESIMS: m/z 580.38 [M + Na]+; Anal. Calcd for
C28H47NO8S: C 60.30, h 8.49, N 2.51, S 5.75. Found: C, 60.17, h 8.42, N 2.29, S 5.60.
(1R)-2,3,4-Tri-O-acetyl-1-[3-(N-tert-butoxycarbonylaminoethylthio)propyl]-5N,6O-oxomethylidene-
1-deoxygalactonojirimycin (27). Yield: 207 mg (97%); Rf = 0.44 (2:1 EtOAc-cyclohexane); [α]D + 64.1
(c 1.0 in DCM); 1H NMR (300 MHz, CDCl3) δ 5.34 (t, 1 H, J3,4 = J4,5 = 2.7 Hz, H-4), 5.23 (dd, 1 H,
J2,3 = 10.9 Hz, J1,2 = 6.4 Hz, H-2), 5.10 (dd, 1 H, H-3), 4.88 (bs, 1 H, NH), 4.33 (m, 1 H, H-1), 4.33 (t, 1 H,
J6a,6b = J5,6a = 8.9 Hz, H-6a), 4.04 (m, 1 H, H-5), 3.97 (dd, 1 H, J5,6b = 3.5 Hz, H-6b), 3.23 (q, 2 H,
3JH,H = 6.5 Hz, CH2NHBoc), 2.50 (m, 4 H, CH2SCH2), 2.11–1.93 (3 s, 9 H, MeCO), 1.80–1.50 (m, 4 H,
CH2), 1.38 (s, 9 H, CMe3); 13C NMR (75.5 MHz, CDCl3) δ 170.4–169.4 (CO ester), 156.8, 155.8 (CO
carbamate), 79.4 (CMe3), 69.0 (C-4), 68.3 (C-3), 66.5 (C-2), 62.8 (C-6), 51.1 (C-5), 50.7 (C-1), 39.8
(CH2NHBoc), 32.1, 30.9 (CH2), 28.4 (CMe3), 25.4, 23.6 (CH2), 20.8-20.6 (MeCO); ESIMS: m/z 555.30
[M + Na]+. Anal. Calcd for C23H36N2O10S: C 51.87, h 6.81, N 5.26, S 6.02. Found: C 51.60, h 6.95, N
5.09, S 5.71.
(1R)-1-[3-(Octylthio)propyl)-5N,6O-oxomethylidene-1-deoxynojirimycin (1). Compound 1 was
obtained by conventional O-deacetylation of 16 (70 mg, 0.14 mmol), as described in general methods,
followed by purification by column chromatography (40:1 EtOAc-MeOH). Yield: 50 mg (95%); Rf = 0.47
(30:1 EtOAc-MeOH); [α]D + 43.9 (c 1.1 in MeOH); 1H NMR (300 MHz, CD3OD) δ 4.45 (t, 1 H,
J6a,6b = J5,6a = 9.0 Hz, H-6a), 4.29 (dd, 1 H, J5,6b = 4.0 Hz, H-6b), 3.96–3.86 (m, 1 H, H-1), 3.66 (ddd, 1 H,
J4,5 = 9.6 Hz, H-5), 3.53–3.40 (m, 2 H, H-2, H-3), 3.28–3.18 (m, 1 H, H-4), 2.66–2.46 (m, 4 H, CH2SCH2),
2.07–1.93 (m, 1 H, CH2), 1.72–1.23 (m, 15 H, CH2), 0.90 (t, 3 H, 3JH,H = 7.0 Hz, CH3); 13C NMR (75.5 MHz,
CD3OD) δ 159.6 (CO), 75.4 (C-4), 74.6–72.1 (C-2, C-3), 67.5 (C-6), 55.3 (C-1, C-5), 33.0–23.7 (CH2), 14.4
(CH3); ESIMS: m/z 398.38 [M + Na]+; Anal. Calcd for C18H33NO5S: C 57.57, h 8.86, N 3.73, S 8.54.
Found: C 57.22, h 8.76, N 3.52, S 8.16.
(1R)-1-[3-(Dodecylthio)propyl]-5N,6O-oxomethylidene-1-deoxynojirimycin (2). Compound 2 was
obtained by conventional O-deacetylation of 17 (59 mg, 0.10 mmol), as described in general methods,
followed by purification by column chromatography (30:1 EtOAc-MeOH). Yield: 41mg (89%); Rf = 0.47
(30:1 EtOAc-MeOH); [α]D + 42.6 (c 1.0 in MeOH); 1H NMR (400 MHz, CD3OD) δ 4.45 (dd, 1 H,
J6a,6b = 9.0 Hz, J5,6a = 8.4 Hz, H-6a), 4.29 (dd, 1 H, J5,6b = 4.0 Hz, H-6b), 3.95–3.88 (m, 1 H, H-1),
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3.66 (ddd, 1 H, J4,5 = 9.5 Hz, H-5), 3.51–3.41 (m, 2 H, H-2, H-3), 3.23 (bt, 1 H, H-4), 2.65–2.48 (m, 4 H,
CH2SCH2), 2.06–1.95 (m, 1 H, CH2), 1.70–1.25 (m, 23 H, CH2), 0.90 (t, 3 H, 3JH,H = 7.0 Hz, CH3);
13C NMR (100.6 MHz, CD3OD) δ 159.7 (CO), 75.4 (C-4), 74.6–72.2 (C-2, C-3), 67.5 (C-6), 55.3 (C-1, C-5),
33.1–23.7 (CH2), 14.4 (CH3); ESIMS: m/z 454.40 [M + Na]+; Anal. Calcd for C22H41NO5S: C 61.22, h 9.57,
N 3.25, S 7.43. Found: C 60.88, h 9.33, N 2.99, S 7.15.
(1R)-1-[3-(N-tert-Butoxycarbonylaminoethylthio)propyl]-5N,6O-oxomethylidene-1- deoxynojirimycin
(3). Compound 3 was obtained by conventional O-deacetylation of 18 (66 mg, 0.12 mmol), as described
in general methods, followed by purification by column chromatography (30:1 EtOAc-MeOH). Yield:
47 mg (92%); Rf = 0.45 (30:1 EtOAc-MeOH); [α]D + 36.2 (c 1.0 in MeOH); 1H NMR (300 MHz, CD3OD)
δ 4.47 (t, 1 H, J6a,6b = J5,6a = 8.5 Hz, H-6a), 4.29 (dd, 1 H, J5,6b = 4.0 Hz, H-6b), 3.97–3.82 (m, 1 H, H-1),
3.66 (ddd, 1 H, J4,5 = 9.6 Hz, H-5), 3.53–3.40 (m, 2 H, H-2, H-3), 3.28–3.11 (m, 3 H, H-4, CH2NHBoc),
2.70–2.50 (m, 4 H, CH2SCH2), 2.05–1.91 (m, 1 H, CH2), 1.72–1.49 (m, 3 H, CH2), 1.44 (s, 9 H, CMe3); 13C
NMR (75.5 MHz, CD3OD) δ 159.7, 158.3 (CO), 80.1 (CMe3), 75.4 (C-4), 74.6–72.1 (C-2, C-3), 67.5 (C-6),
55.3 (C-1, C-5), 41.4 (CH2NHBoc), 32.5–24.5 (CH2), 28.8 (CMe3); ESIMS: m/z 429.31 [M + Na]+; Anal.
Calcd for C17H30N2O7S: C 50.23, h 7.44, N 6.89, S 7.89. Found: C 50.37, h 7.60, N 6.58, S 7.61.
(1R)-1-[3-(Octylthio)propyl]-5N,6O-oxomethylidene-1-deoxygalactonojirimycin (7). Compound 7 was
obtained by conventional O-deacetylation of 25 (103 mg, 0.21 mmol) followed by purification by
column chromatography (30:1 EtOAc-MeOH). Yield: 74 mg (96%); Rf = 0.19 (30:1 EtOAc-MeOH);
[α]D + 31.0 (c 1.1 in MeOH); 1H NMR (300 MHz, CD3OD) δ 4.31 (dd, 1 H, J6a,6b = 8.6 Hz, J5,6a = 4.6 Hz,
H-6a), 4.26 (t, 1 H, J5,6b = 8.6 Hz, H-6b), 3.91 (m, 2 H, H-1, H-5), 3.81 (dd, 1 H, J2,3 = 9.7 Hz, J1,2 = 6.4 Hz,
H-2), 3.71 (t, 1 H, J3,4 = J4,5 = 2.3 Hz, H-4), 3.51 (dd, 1 H, H-3), 2.46 (m, 4 H, CH2SCH2), 1.95–1.36 (m, 6 H,
CH2), 1.26 (m, 10 H, CH2), 0.80 (t, 3 H, 3JH,H = 6.9 Hz, CH3); 13C NMR (75.5 MHz, CD3OD) δ 160.4
(CO), 71.4 (C-3), 71.1 (C-4), 68.1 (C-2), 64.9 (C-6), 55.1 (C-5), 54.6 (C-1), 33.0–23.7 (CH2), 14.5 (CH3);
ESIMS: m/z 398.36 [M + Na]+; Anal. Calcd for C18H33NO5S: C 57.57, h 8.86, N 3.73, S 8.54. Found:
C 57.26, h 8.64, N 3.46, S 8.23.
(1R)-1-[3-(Dodecylthio)propyl]-5N,6O-oxomethylidene-1-deoxygalactonojirimycin (8). Compound
8 was obtained by conventional O-deacetylation of 26 (86 mg, 0.15 mmol) followed by purification
by column chromatography (30:1 EtOAc-MeOH). Yield: 58 mg (87%); Rf = 0.31 (30:1 EtOAc-MeOH);
[α]D + 27.2 (c 1.1 in MeOH); 1H NMR (300 MHz, CD3OD) δ 4.43 (dd, 1 H, J6a,6b = 8.6 Hz, J5,6a = 4.4 Hz,
H-6a), 4.37 (t, 1 H, J5,6b = 8.6 Hz, H-6b), 4.02 (m, 2 H, H-1, H-5), 3.93 (dd, 1 H, J2,3 = 9.7 Hz, J1,2 = 6.4 Hz,
H-2), 3.82 (t, 1 H, J3,4 = J4,5 = 2.3 Hz, H-4), 3.62 (dd, 1 H, H-3), 2.65–2.49 (m, 4 H, CH2SCH2),
2.04–1.38 (m, 6 H, CH2), 1.37 (m, 18 H, CH2), 0.98 (t, 3 H, 3JH,H = 6.9 Hz, CH3); 13C NMR (75.5 MHz,
CD3OD) δ 160.4 (CO), 71.4 (C-3), 71.1 (C-4), 68.1 (C-2), 64.9 (C-6), 55.1 (C-5), 54.6 (C-1), 33.1–23.7 (CH2),
14.4 (CH3); ESIMS: m/z 454.39 [M + Na]+; Anal. Calcd for C22H41NO5S: C 61.22, h 9.57, N 3.25, S 7.43.
Found: C 60.95, h 9.28, N 2.98, S 7.14.
(1R)-1-[3-(N-tert-Butoxycarbonylaminoethylthio)propyl]-5N,6O-oxomethylidene-1-deoxygalactonojirimy
cin (9). Compound 9 was obtained by conventional O-deacetylation of 27 (72 mg, 0.14 mmol) followed
by purification by column chromatography (30:1 EtOAc-MeOH). Yield: 52 mg (95%); Rf = 0.15
(30:1 EtOAc-MeOH); [α]D + 26.2 (c 1.0 in MeOH); 1H NMR (300 MHz, CD3OD) δ 4.31 (dd, 1 H,
J6a,6b = 8.5 Hz, J5,6a = 4.9 Hz, H-6a), 4.27 (t, 1 H, J5,6b = 8.5 Hz, H-6b), 3.95 (m, 2 H, H-1, H-5),
3.82 (dd, 1 H, J2,3 = 9.7 Hz, J1,2 = 6.4 Hz, H-2), 3.71 (t, 1 H, J3,4 = J4,5 = 2.3 Hz, H-4), 3.51 (dd, 1 H, H-3),
3.11 (t, 2 H, 3JH,H = 6.9 Hz, CH2NHBoc), 2.59–2.41 (m, 4 H, CH2SCH2), 1.93–1.40 (m, 6 H, CH2), 1.34 (s,
9 H, CMe3); 13C NMR (75.5 MHz, CD3OD) δ 160.4, 158.3 (CO), 80.1 (CMe3), 71.4 (C-3), 71.1 (C-4), 68.1
(C-2), 64.9 (C-6), 55.1 (C-5), 54.6 (C-1), 41.4 (CH2NHBoc), 32.5, 32.2 (CH2), 28.8 (CMe3), 27.5, 24.0 (CH2);
ESIMS: m/z 429.26 [M + Na]+; Anal. Calcd for C17H30N2O7S: C 50.23, h 7.44, N 6.89, S 7.89. Found: C
50.01, h 7.33, N 6.58, S 7.62.
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3.5. General Procedure for the Synthesis of Sulfone Derivatives of ONJ 4–6 and OGJ 10–12
To a solution of the corresponding sulfide precursor (16–18, 25–27) (0.13 mmol) in DCM (3 mL),
70% mCPBA (0.26 mmol) was added at 0 ◦C. The reaction mixture was stirred for 30–60 min, diluted
with DCM (50 mL), washed with aqueous NaHCO3 (2 × 10 mL), brine (10 mL), dried (MgSO4),
and concentrated. The resulting residue was purified by column chromatography using the solvent
indicated in each case.
(1R)-2,3,4-Tri-O-acetyl-1-[3-(octylsulfonyl)propyl]-5N,6O-oxomethylidene-1-deoxynojirimycin (19).
Column chromatography (1:1 EtOAc-cyclohexane). Yield: 179 mg (96%); Rf = 0.50
(2:1 EtOAc-cyclohexane); [α]D + 41.3 (c 0.9 in DCM); 1H NMR (300 MHz, CDCl3) δ 5.27 (t, 1 H,
J2,3 = J3,4 = 9.6 Hz, H-3), 5.03 (dd, 1 H, J1,2 = 6.0 Hz, H-2), 4.96 (t, 1 H, J4,5 = 9.6 Hz, H-4), 4.40 (t, 1 H,
J6a,6b = J5,6a = 8.5 Hz, H-6a), 4.32–4.20 (m, 1 H, H-1), 4.24 (dd, 1 H, J5,6b = 4.5 Hz, H-6b), 3.86 (ddd, 1 H,
H-5), 3.14–2.86 (m, 4 H, CH2SO2CH2), 2.04–1.99 (3 s, 9 H, MeCO), 1.97–1.18 (m, 16 H, CH2), 0.85 (t, 3 H,
3JH,H = 7.0 Hz, CH3); 13C NMR (75.5 MHz, CDCl3) δ 169.9–169.3 (CO ester), 156.5 (CO carbamate),
72.2 (C-4), 69.6 (C-3), 69.3 (C-2), 65.8 (C-6), 53.4 (CH2SO2), 52.0 (C-5), 50.9 (CH2SO2), 50.2 (C-1), 31.7–18.2
(CH2), 20.6–20.5 (MeCO), 14.1 (CH3); ESIMS: m/z 556.29 [M + Na]+; Anal. Calcd for C24H39NO10S: C
54.02, h 7.37, N 2.62, S 6.01. Found: C 54.24, h 7.50, N 2.36, S 5.77.
(1R)-2,3,4-Tri-O-acetyl-1-[3-(dodecylsulfonyl)propyl]-5N,6O-oxomethylidene-1-deoxynojirimycin (20).
Column chromatography (1:1 EtOAc-cyclohexane). Yield: 46.5 mg (87%); Rf = 0.52
(2:1 EtOAc-cyclohexane); [α]D + 30.7 (c 1.1 in DCM); 1H NMR (300 MHz, CDCl3) δ 5.27 (t, 1 H,
J2,3 = J3,4 = 10.0 Hz, H-3), 5.03 (dd, 1 H, J1,2 = 6.0 Hz, H-2), 4.95 (t, 1 H, J4,5 = 9.6 Hz, H-4), 4.40 (t, 1 H,
J6a,6b = J5,6a = 8.5 Hz, H-6a), 4.33–4.20 (m, 1 H, H-1), 4.24 (dd, 1 H, J5,6b = 4.5 Hz, H-6b), 3.86 (ddd, 1 H,
H-5), 3.15–2.87 (m, 4 H, CH2SO2CH2), 2.04–2.00 (3 s, 9 H, MeCO), 1.96–1.18 (m, 24 H, CH2), 0.85 (t, 3 H,
3JH,H = 7.0 Hz, CH3); 13C NMR (75.5 MHz, CDCl3) δ 169.9–169.3 (CO ester), 156.5 (CO carbamate),
72.2 (C-4), 69.6 (C-3), 69.3 (C-2), 65.8 (C-6), 53.4 (CH2SO2), 52.0 (C-5), 50.9 (CH2SO2), 50.2 (C-1), 31.9–18.2
(CH2), 20.6–20.5 (MeCO), 14.1 (CH3); ESIMS: m/z 612.47 [M + Na]+; Anal. Calcd for C28H47NO10S:
C 57.03, h 8.03, N 2.38, S 5.44. Found: C 57.28, h 8.17, N 2.06, S 5.24.
(1R)-2,3,4-Tri-O-acetyl-1-[3-(N-tert-butoxycarbonylaminoethylsulfonyl)propyl]-5N,6O-oxomethylidene-
1-deoxynojirimycin (21). Column chromatography (1:1 EtOAc-cyclohexane). Yield: 60 mg (83%);
Rf = 0.23 (2:1 EtOAc-cyclohexane); [α]D + 30.7 (c 1.1 in DCM); 1H NMR (300 MHz, CDCl3) δ 5.30 (t, 1 H,
J2,3 = J3,4 = 10.2 Hz, H-3), 5.04 (dd, 1 H, J1,2 = 6.3 Hz, H-2), 4.97 (t, 1 H, J4,5 = 9.5 Hz, H-4), 4.43 (t, 1 H,
J6a,6b = J5,6a = 8.4 Hz, H-6a), 4.34–4.22 (m, 2 H, H-1, H-6b), 3.87 (ddd, 1 H, J5,6b = 4.5 Hz, H-5),
3.60 (q, 2 H, J = 6.0 Hz, CH2NHBoc), 3.23–2.93 (m, 4 H, CH2SO2CH2), 2.06–2.01 (3 s, 9 H, MeCO),
1.98–1.76 (m, 4 H, CH2), 1.43 (s, 9 H, CMe3); 13C NMR (75.5 MHz, CDCl3) δ 169.9–169.3 (CO ester),
156.6, 155.7 (CO carbamate), 80.0 (CMe3), 72.2 (C-4), 69.6 (C-3), 69.3 (C-2), 65.9 (C-6), 53.0 (CH2SO2),
52.0, 51.9 (C-5, CH2SO2), 50.0 (C-1), 34.4 (CH2NHBoc), 28.3 (CMe3), 23.9 (CH2), 20.6–20.5 (MeCO),
18.1 (CH2); ESIMS: m/z 587.22 [M + Na]+; Anal. Calcd for C23H36N2O12S: C 48.93, h 6.43, N 4.96, S 5.68.
Found: C 49.14, h 6.50, N 4.79, S 5.46.
(1R)-2,3,4-Tri-O-acetyl-1-[3-(octylsulfonyl)propyl]-5N,6O-oxomethylidene-1- deoxygalactonojirimycin
(28). Column chromatography (1:1 → 2:1 EtOAc-cyclohexane). Yield: 79 mg (92%); Rf = 0.34
(2:1 EtOAc-cyclohexane); [α]D + 5.6 (c 1.0 in DCM); 1H NMR (300 MHz, CDCl3) δ 5.42 (t, 1 H,
J3,4 = J4,5 = 2.7 Hz, H-4), 5.32 (dd, 1 H, J2,3 = 10.9 Hz, J1,2 = 6.5 Hz, H-2), 5.13 (dd, 1 H, H-3), 4.43 (m, 1 H,
H-1), 4.42 (t, 1 H, J6a,6b = J5,6a = 8.9 Hz, H-6a), 4.14 (m, 1 H, H-5), 4.07 (dd, 1 H, J5,6b = 3.5 Hz, H-6b),
3.16–2.93 (m, 4 H, CH2SO2CH2), 2.20–2.02 (3 s, 9 H, MeCO), 2.12–1.78 (m, 6 H, CH2), 1.37 (m, 10 H,
CH2), 0.90 (t, 3 H, 3JH,H = 7.0 Hz, CH3); 13C NMR (75.5 MHz, CDCl3) δ 170.4–169.5 (CO ester), 157.0
(CO carbamate), 68.9 (C-4), 68.3 (C-3), 66.4 (C-2), 63.0 (C-6), CH2SO2 (53.4), 51.0 (C-5), 50.9 (C-1), 50.4
(CH2SO2), 31.9–21.9 (CH2), 20.7–20.6 (MeCO), 18.4 (CH2), 14.0 (CH3); ESIMS: m/z 556.27 [M + Na]+;
Anal. Calcd for C24H39NO10S: C 54.02, h 7.37, N 2.62, S 6.01. Found: C 53.88, h 7.42, N 2.41, S 5.69.
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(1R)-2,3,4-Tri-O-acetyl-1-[3-(dodecylsulfonyl)propyl]-5N,6O-oxomethylidene-1-deoxygalactonojirimy
cin (29). Column chromatography (1:1→ 2:1 EtOAc-cyclohexane). Yield: 72 mg (76%); Rf = 0.45 (2:1
EtOAc-cyclohexane); [α]D + 5.8 (c 1.0 in DCM); 1H NMR (300 MHz, CDCl3) δ 5.34 (m, 1 H, H-4),
5.23 (dd, 1 H, J2,3 = 10.9 Hz, J1,2 = 6.4 Hz, H-2), 5.10 (dd, 1 H, J3,4 = 2.6 Hz, H-3), 4.34 (m, 1 H, H-1),
4.33 (t, 1 H, J6a,6b = J5,6a = 9.0 Hz, H-6a), 4.08 (m, 1 H, H-5), 3.98 (dd, 1 H, J5,6b = 3.4 Hz, H-6b),
3.13–2.85 (m, 4 H, CH2SO2CH2), 2.11–1.93 (3 s, 9 H, MeCO), 1.84–1.30 (m, 6 H, CH2), 1.19 (m, 18 H,
CH2), 0.81 (t, 3 H, 3JH,H = 6.9 Hz, CH3); 13C NMR (75.5 MHz, CDCl3) δ 170.4, 170.0, 169.5 (CO ester),
157.0 (CO carbamate), 68.9 (C-4), 68.2 (C-3), 66.4 (C-2), 62.9 (C-6), 53.5 (CH2SO2), 51.0 (C-5), 50.8
(C-1), 50.4 (CH2SO2), 31.9–21.9 (CH2), 20.7–20.5 (MeCO), 18.4 (CH2), 14.1 (CH3); ESIMS: m/z 612.26
[M + Na]+; Anal. Calcd for C24H47NO10S: C 57.03, h 8.03, N 2.38, S 5.44. Found: C 57.14, h 8.23, N 2.17,
S 5.16.
(1R)-2,3,4-Tri-O-acetyl-1-[3-(N-tert-butoxycarbonylaminoethylsulfonyl)propyl]-5N,6O-
oxomethylidene-1-deoxygalactonojirimycin (30). Column chromatography (1:1 → 2:1 → 3:1
EtOAc-cyclohexane). Yield: 77 mg (85%); Rf = 0.24 (2:1 EtOAc-cyclohexane); [α]D + 44.8 (c 1.1 in
DCM); 1H NMR (300 MHz, CDCl3) δ 5.34 (m, 1 H, H-4), 5.23 (dd, 1 H, J2,3 = 10.9 Hz, J1,2 = 6.4 Hz,
H-2), 5.05 (dd, 1 H, J3,4 = 2.6 Hz, H-3), 4.37 (m, 1 H, H-1), 4.36 (t, 1 H, J6a,6b = J5,6a = 9.0 Hz, H-6a),
4.08 (m, 1 H, H-5), 3.98 (dd, 1 H, J5,6b = 3.4 Hz, H-6b), 3.54 (q, 2 H, 3JH,H = 6.0 Hz, CH2NHBoc),
3.15–2.90 (m, 4 H, CH2SO2CH2), 2.12–1.93 (3 s, 9 H, MeCO), 1.99–1.66 (m, 4 H, CH2), 1.37 (s, 9 H,
CMe3); 13C NMR (75.5 MHz, CDCl3) δ 170.4–169.5 (CO ester), 157.0, 155.8 (CO carbamate), 80.0 (CMe3),
68.9 (C-4), 68.2 (C-3), 66.3 (C-2), 63.0 (C-6), 53.0, 51.9 (CH2SO2), 51.0 (C-5), 50.3 (C-1), 34.5 (CH2NHBoc),
29.7 (CH2), 28.3 (CMe3), 23.5 (CH2), 20.7–20.5 (MeCO); ESIMS: m/z 587.24 [M + Na]+; Anal. Calcd for
C23H36N2O12S: C 48.93, h 6.43, N 4.96, S 5.68. Found: C 49.11, h 6.51, N 4.72, S 5.46.
(1R)-1-[3-(Octylsulfonyl)propyl]-5N,6O-oxomethylidene-1-deoxynojirimycin (4). Compound 4 was
obtained by conventional O-deacetylation of 19 (96 mg, 0.18 mmol), as described in general methods,
followed by purification by column chromatography (30:1 EtOAc-MeOH). Yield: 62 mg (85%); Rf = 0.27
(30:1 EtOAc-MeOH); [α]D + 51.8 (c 0.8 in MeOH); 1H NMR (300 MHz, CD3OD) δ 4.48 (t, 1 H,
J6a,6b = J5,6a = 8.5 Hz, H-6a), 4.30 (dd, 1 H, J5,6b = 3.9 Hz, H-6b), 3.93 (ddd, 1 H, J1,CH = 11.7 Hz,
J1,2 = 5.7 Hz, J1,CH´ = 3.3 Hz, H-1), 3.69 (ddd, 1 H, J4,5 = 9.6 Hz, H-5), 3.55–3.40 (m, 2 H, H-2, H-3),
3.29–3.00 (m, 5 H, H-4, CH2SO2CH2), 2.10–1.58 (m, 6 H, CH2), 1.52–1.22 (m, 10 H, CH2), 0.91 (t, 3
H, 3JH,H = 7.0 Hz, CH3); 13C NMR (75.5 MHz, CD3OD) δ 159.7 (CO), 75.3 (C-4), 74.6, 72.0 (C-2, C-3),
67.6 (C-6), 55.2 (C-5), 55.0 (C-1), 53.5, 52.6 (CH2SO2CH2), 32.9–19.8 (CH2), 14.4 (CH3); ESIMS: m/z 430.32
[M + Na]+; Anal. Calcd for C18H33NO7S: C 53.05, h 8.16, N 3.44, S 7.87. Found: C 52.81, h 7.98,
N 3.11, S 7.49.
(1R)-1-[3-(Dodecylsulfonyl)propyl]-5N,6O-oxomethylidene-1-deoxynojirimycin (5). Compound 5
was obtained by conventional O-deacetylation of 20 (34 mg, 0.058 mmol), as described in general
methods, followed by purification by column chromatography (50:1→ 30:1→ 15:1 EtOAc-MeOH).
Yield: 22 mg (83%); Rf = 0.33 (30:1 EtOAc-MeOH); [α]D + 34.4 (c 0.9 in MeOH); 1H NMR (300 MHz,
CD3OD) δ 4.48 (t, 1 H, J6a,6b = J5,6a = 8.5 Hz, H-6a), 4.30 (dd, 1 H, J5,6b = 3.9 Hz, H-6b), 3.93 (ddd, 1 H,
3J1,CH = 11.7 Hz, J1,2 = 5.7 Hz, 3J1,CH´ = 3.0 Hz, H-1), 3.69 (ddd, 1 H, J4,5 = 10.0 Hz, H-5), 3.55–3.39 (m, 2 H,
H-2, H-3), 3.29–3.14 (m, 2 H, H-4, CH2SO2), 3.12–3.00 (m, 3 H, CH2SO2CH2), 2.10–1.25 (m, 24 H, CH2),
0.90 (t, 3 H, 3JH,H = 7.0 Hz, CH3); 13C NMR (75.5 MHz, CD3OD) δ 159.8 (CO), 75.4 (C-4), 74.6, 72.0 (C-2,
C-3), 67.6 (C-6), 55.3 (C-5), 55.1 (C-1), 53.5, 52.7 (CH2SO2CH2), 33.1–19.8 (CH2), 14.4 (CH3); ESIMS: m/z
486.41 [M + Na]+. Anal. Calcd for C22H41NO7S: C 56.99, h 8.91, N 3.02, S 6.91. Found: C 56.67, h 8.73,
N 2.78, S 6.53.
(1R)-1-[3-(N-tert-Butoxycarbonylaminoethylsulfonyl)propyl]-5N,6O-oxomethylidene-1-deoxynojirimy
cin (6). Compound 6 was obtained by conventional O-deacetylation of 21 (35.6 mg, 0.06 mmol), as
described in general methods, followed by purification by column chromatography (30:1 → 10:1
EtOAc:MeOH). Yield: 22 mg (80%); Rf = 0.33 (10:1 EtOAc-MeOH); [α]D + 26.5 (c 1.0 in MeOH);
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1H NMR (300 MHz, CD3OD) δ 4.49 (dd, 1 H, J6a,6b = 9.0 Hz, J5,6a = 8.1 Hz, H-6a), 4.30 (dd, 1 H,
J5,6b = 3.9 Hz, H-6b), 3.93 (ddd, 1 H, 3J1,CH = 11.7 Hz, J1,2 = 5.7 Hz, 3J1,CH´ = 3.0 Hz, H-1), 3.69 (ddd, 1 H,
J4,5 = 9.6 Hz, H-5), 3.54–3.39 (m, 4 H, H-2, H-3, CH2NHBoc), 3.29–3.05 (m, 5 H, H-4, CH2SO2CH2),
2.10–1.58 (m, 4 H, CH2), 1.44 (s, 9 H, CMe3); 13C NMR (75.5 MHz, CD3OD) δ 159.8 (CO), 80.6
(CMe3), 75.3 (C-4), 74.6, 72.0 (C-2, C-3), 67.6 (C-6), 55.3 (C-5), 55.1 (C-1), 53.5, 53.1 (CH2SO2CH2),
35.3 (CH2NHBoc), 28.7 (CMe3), 24.6–19.8 (CH2); ESIMS: m/z 461.22 [M + Na]+; Anal. Calcd for
C17H30N2O9S: C 46.57, h 6.90, N 6.39, S 7.31. Found: C 46.23, h 6.69, N 6.08, S 6.95.
(1R)-1-[3-(Octylsulfonyl)propyl]-5N,6O-oxomethylidene-1-deoxygalactonojirimycin (10). Compound
10 was obtained by conventional O-deacetylation of 28 (73 mg, 0.14 mmol) followed by purification
by column chromatography (50:1→ 30:1→ 15:1 EtOAc-MeOH). Yield: 50 mg (90%); Rf = 0.30 (9:1
EtOAc-MeOH); [α]D + 29.6 (c 1.0 in MeOH); 1H NMR (500 MHz, 3:7 CDCl3-CD3OD) δ 4.43 (dd, 1 H,
J6a,6b = 8.6 Hz, J5,6a = 4.3 Hz, H-6a), 4.39 (t, 1 H, J5,6b = 8.6 Hz, H-6b), 4.00 (m, 2 H, H-1, H-5),
3.95 (dd, 1 H, J2,3 = 10.0 Hz, J1,2 = 6.5 Hz, H-2), 3.82 (t, 1 H, J3,4 = 2.8 Hz, H-4), 3.60 (dd, 1 H, H-3),
3.21 (ddd, 1 H, 2JH,H = 15.1 Hz, 3JH,H = 9.7 Hz, 3JH,H = 5.6 Hz,CHSO2), 3.03 (m, 3 H, CHSO2, CH2SO2),
2.06–1.61 (m, 6 H, CH2), 1.50–1.28 (m, 10 H, CH2), 0.90 (t, 3 H, 3JH,H = 7.1 Hz, CH3); 13C NMR
(125.7 MHz, 3:7 CDCl3-CD3OD) δ 160.0 (CO), 71.0 (C-3), 70.5 (C-4), 67.5 (C-2), 64.5 (C-6), 55.3 (C-5),
54.1 (C-1), 53.4, 52.4 (CH2SO2CH2), 32.5–19.6 (CH2), 14.3 (CH3); ESIMS: m/z 430.32 [M + Na]+; Anal.
Calcd for C18H33NO7S: C 53.05, h 8.16, N 3.44, S 7.87. Found: C 52.74, h 7.89, N 3.19, S 7.51.
(1R)-1-[3-(Dodecylsulfonyl)propyl]-5N,6O-oxomethylidene-1-deoxygalactonojirimycin (11). Compound
11 was obtained by conventional O-deacetylation of 29 (56 mg, 0.09 mmol) followed by purification
by column chromatography (50:1→ 30:1→ 15:1 EtOAc-MeOH). Yield: 35 mg (80%); Rf = 0.30 (30:1
EtOAc-MeOH); [α]D + 26.0 (c 1.1 in MeOH); 1H NMR (500 MHz, 3:7 CDCl3-CD3OD) δ 4.44 (dd, 1 H,
J6a,6b = 8.6 Hz, J5,6a = 4.2 Hz, H-6a), 4.39 (t, 1 H, J5,6b = 8.6 Hz, H-6b), 4.00 (m, 2 H, H-1, H-5),
3.95 (dd, 1 H, J2,3 = 10.0 Hz, J1,2 = 6.5 Hz, H-2), 3.82 (t, 1 H, J3,4 = 2.8 Hz, H-4), 3.60 (dd, 1 H, H-3),
3.21 (ddd, 1 H, 2JH,H = 15.1 Hz, 3JH,H = 9.6 Hz, 3JH,H = 5.6 Hz,CHSO2), 3.03 (m, 3 H, CHSO2, CH2SO2),
2.03–1.63 (m, 6 H, CH2), 1.50–1.29 (m, 18 H, CH2), 0.89 (t, 3 H, 3JH,H = 6.8 Hz, CH3); 13C NMR
(125.7 MHz, 3:7 CDCl3-CD3OD) δ 160.0 (CO), 71.1 (C-3), 70.6 (C-4), 67.5 (C-2), 64.6 (C-6), 54.4 (C-5),
54.2 (C-1), 53.4, 52.4 (CH2SO2CH2), 32.7–19.6 (CH2), 14.4 (CH3); ESIMS: m/z 486.38 [M + Na]+; Anal.
Calcd for C22H41NO7S: C 56.99, h 8.91, N 3.02, S 6.91. Found: C 56.87, h 8.79, N 2.85, S 6.70.
(1R)-1-[3-(N-tert-Butoxycarbonylaminoethylsulfonyl)propyl]-5N,6O-oxomethylidene-1-
deoxygalactonojirimycin (12). Compound 12 was obtained by conventional O-deacetylation
of 30 (66 mg, 0.12 mmol) followed by purification by column chromatography (30:1 → 10:1 → 5:1
EtOAc-MeOH). Yield: 47 mg (92%); Rf = 0.29 (9:1 EtOAc-MeOH); [α]D + 20.7 (c 1.0 in MeOH);
1H NMR (500 MHz, 3:7 CDCl3-CD3OD) δ 4.35 (dd, 1 H, J6a,6b = 8.5 Hz, J5,6a = 4.7 Hz, H-6a),
4.31 (t, 1 H, J5,6b = 8.5 Hz, H-6b), 3.92 (m, 2 H, H-1, H-5), 3.85 (dd, 1 H, J2,3 = 9.7 Hz, J1,2 = 6.5 Hz,
H-2), 3.72 (t, 1 H, J3,4 = 2.7 Hz, H-4), 3.50 (dd, 1 H, H-3), 3.44 (t, 2 H, 3JH,H = 6.7 Hz, CH2NHBoc),
3.15 (m, 3 H, CHSO2, CH2SO2), 2.98 (ddd, 1 H, 2JH,H = 14.2 Hz, 3JH,H = 9.3 Hz, 3JH,H = 5.9 Hz,CHSO2),
1.99–1.47 (m, 4 H, CH2), 1.35 (s, 9 H, CMe3); 13C NMR (75.5 MHz, 3:7 CDCl3-CD3OD) δ 160.0,
157.6 (CO), 80.5 (CMe3), 71.0 (C-3), 70.5 (C-4), 67.5 (C-2), 64.5 (C-6), 54.3 (C-5), 54.1 (C-1), 53.2, 52.9
(CH2SO2CH2), 35.0 (CH2NHBoc), 28.6 (CMe3), 23.7, 19.5 (CH2); ESIMS: m/z 461.25 [M + Na]+; Anal.
Calcd for C17H30N2O9S: C 46.57, h 6.90, N 6.39, S 7.31. Found: C 46.28, h 6.69, N 6.11, S 7.03.
3.6. General Procedure for Antiproliferative Assays
All reagents were used as purchased from commercial suppliers without further purification.
The human solid tumor cell lines A549 (lung), HBL-100 (breast), HeLa (cervix), SW1573 (lung), T-47D
(breast), and WiDr (colon) were used in this study. These cell lines were a kind gift from Prof. G. J.
Peters (VU Medical Center, Amsterdam, The Netherlands).
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Cells were inoculated onto 96-well microtiter plates in a volume of 100 µL per well at densities
of 2500 (A549, HBL-100, HeLa, and SW1573) and 5000 (T-47D and WiDr) cells per well, based on
their doubling times. Compounds were initially dissolved in DMSO at 400 times the desired final
maximum test concentration. Control cells were exposed to an equivalent concentration of DMSO
(0.25% v/v, negative control). Each agent was tested in triplicate at different dilutions in the range
of 1 to 100 µM. The drug treatment started on day 1 after plating. Drug incubation times were 48 h,
after which cells were precipitated with 25 µL ice-cold TCA (50% w/v) and fixed for 60 min at 4 ◦C.
Then the SRB assay was performed. The optical density (OD) of each well was measured at 530 nm,
using BioTek’s PowerWave XS Absorbance Microplate Reader. Values were corrected for background
OD from wells only containing medium. The antiproliferative activity for each compound, expressed
as GI50 values, was calculated according to NCI formulas [69].
3.7. General Procedure for Antileishmanial Assays
3.7.1. Leishmania Culture Conditions
For the biological assays, stock solutions of the synthesized compounds in DMSO at 10 mM
were prepared. Triton X-100, paraformaldehyde, 3-(4,5-dimethyltriazol-2-yl)-2,5-diphenyltetrazolium
bromide (MTT), resazurin and phorbol 12-myristate 13-acetate (PMA), were purchased from
Sigma-Aldrich (St. Louis, MO, USA). Amphotericine was purchased from Zentaris GmbH (Frankfurt
am Main, Germany). DMNPE-luciferin {D-luciferin-1[-(4,5-dimethoxy-2-nitrophenyl) ethyl ester]},
hygromycin B, and 4,6-diamidino-2-phenylindole dihydrochloride (DAPI) were purchased from
Invitrogen (Carlsbad, CA, USA). Kit Luciferase Assay System was purchased from Promega.
L-glutamine and penicillin/streptomycin were obtained from Gibco.
3.7.2. Cell lines Culture and Determination of Cellular Toxicity
Human myelomonocytic cell line THP-1 was grown at 37 ◦C and 5% CO2 in RPMI-1640
supplemented with 10% iFBS, 2 mM glutamate, 100 U/mL penicillin, and 100 µg/mL streptomycin;
3 × 104 cells/well in 96-well plates were differentiated to macrophages with 20 ng/mL of PMA treatment
for 48 h followed by 24 h of culture in fresh medium [70]. Cellular toxicity of all compounds was
determined using the colorimetric MTT-based assay after incubation at 37 ◦C for 72 h in the presence
of increasing concentrations of compounds [71]. The results are expressed as EC50 values, as the
concentration of compound that reduce cell growth by 50% versus untreated control cells.
3.7.3. Susceptibility Analysis in Intracellular Leishmania Amastigotes.
Macrophage-differentiated THP-1 cells, which are considered a suitable model for human
macrophages, were plated at a density of 3 × 104 or 3 × 105 macrophages/well in 96-well white
polystyrene microplates or 24-well tissue culture chamber slides, respectively, and were infected at
a macrophage/parasite ratio of 1:10 with L. donovani promastigotes. Twenty-four hours after infection
at 35 ◦C and 5% CO2, extracellular parasites were removed by washing with serum-free medium.
Infected cell cultures were then incubated at different compound concentrations in RPMI 1640 medium
plus 10% iFBS at 37 ◦C with 5% CO2 for 72 h. To determine the susceptibility of L. donovani LUC
amastigotes, infected macrophages maintained in 96-well plates were lysed and then luminescence
intensity was measured as indicative of the intracellular parasite growth, using the Luciferase Assay
System Kit (Promega, Madison, Wis.) according to the instructions of the supplier. To determine the
susceptibility of L. donovani HU3 amastigotes, infected macrophages maintained in 24-well plates were
fixed for 30 min at 4 ◦C with 2.5% paraformaldehyde phosphate-buffered saline (PBS; 1.2 mM KH2PO4,
8.1 mM Na2HPO4, 130 mM NaCl, and 2.6 mM KCl adjusted to pH 7) and permeabilized with 0.1%
Triton X-100 in PBS for 30 min. Intracellular parasites and macrophages were detected by nuclear
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staining with ProLong® Gold antifade reagent plus DAPI (Invitrogen). The percentage infection and
mean number of amastigotes from infected macrophages were determined with 200 macrophages/well.
Supplementary Materials: The following are available online at www.mdpi.com/1420-3049/24/16/2882/s1.
Figures S1–S28: 1H and 13C NMR spectra of the new compounds 1–12, 15, 24, Figures S29–S45: selected
Dixon and Lineweaver–Burk plots for Ki determinations and Figure S46: Antiproliferative activity (GI50) of
new compounds.
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